NKTR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nektar Therapeutics is not a strong buy for a beginner, long-term investor at this moment. While there are positive catalysts like analyst optimism and potential market opportunities for its lead drug, significant risks such as ongoing lawsuits, poor financial performance, and hedge fund selling outweigh the positives. The technical indicators suggest a bullish trend, but the lack of proprietary trading signals and the negative sentiment from legal challenges make it prudent to hold rather than buy.
The stock shows a bullish trend with MACD positively expanding, RSI in a neutral zone, and moving averages indicating upward momentum (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 83.229), which could limit immediate upside potential.
Positive data from Phase 2 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata, with potential for significant market share.
Nektar is facing multiple class action lawsuits related to its REZOLVE-AA trial, which could harm investor confidence and future R&D. Hedge funds are aggressively selling the stock, with a 1229.84% increase in selling activity last quarter. Poor financial performance in Q4 2025, with revenue down 25.25% YoY and net income plummeting by 596.89%.
The company's Q4 2025 financials are weak, with revenue dropping to $21.8M (-25.25% YoY), net income at -$36.08M (-596.89% YoY), and EPS at -1.77 (-440.38% YoY). Gross margin improved to 100%, but this is overshadowed by the significant losses.
Analysts are generally optimistic, with most maintaining buy ratings and price targets ranging from $70 to $165. Citi and Oppenheimer have high price targets of $123 and $140, respectively, citing potential catalysts like rezpegaldesleukin's market opportunities. However, Wedbush has a neutral rating, citing limited immediate upside.
